PCT



(51) International Patent Classification 6:	ا ا	(11) International Publication Number: WO 96/4164		
A61K 45/06	(43) International Publication Date: 27 December 1996			
221 International Application Number: PCT/US: 222 International Filing Date: 11 June 1996 (1.206.95) 309 Priority Data: 08/489,415 12 June 1995 (12.06.95) 710 Applicant: G.D. SEARLE & CO. [US/US]; Corpora Dept., P.O. Box 5110, Chicago, IL 6689-5110 721 Inventors: IRASKON, Penc. C. 2292 Ridgley (Voc. Clarkson Valley, MO 63065 (US). ANDERSO MO 63043 (US). GREGORY, Susan, A. 4404 Modelward #20A, St. Louis, MO 63016 (US). 744 Agents: BULOCK, Joseph, W. et al.; G.D. Scarle Corporate Patent Dept., P.O. Box 5110, Chicago, I. 5110 (US).	tte Pate US). ds Driv N, Gar Height O Linde	CA, CH, CN, CZ, DE, DX, EE, ES, FI, GB, GE, HU, I SI, P, KE, KG, KP, KR, KZ, LK, LK, LS, LT, LU, L MD, MG, MK, MM, MW, MX, NO, NZ, PL, PT, RO, R SD, SE, GS, SI, SK, TT, TM, TR, TT, UA, UG, UZ, V ARPO patent (KE, LS, MW, SD, SZ, UG). Eurasian pate (AM, AZ, BY, KG, KZ, MD, RU, TI, TW), European pate (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, TE, TT, L MC, NL, FT, SE), OAPI patent (BP, BJ, CF, CG, CI, CI GA, GN, ML, MR, NE, SN, TD, TG). Ce, With invernational search report. Before the expiration of the time limit for amending to claims and to be republished in the event of the recept amendments.		
THE TREATMENT OF INFLAMMATIONS (57) Abstract		IIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FO		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi	
AT	Austria	GE	Georgia	MX	Mexico	
AU	Australia	GN	Guinea	NE	Niger	
BB	Barbados	GR	Greece	NL	Netherlands	
BE	Belgium	HU	Hungary	NO	Norway	
BF	Burkina Faso	IE	Ireland	NZ	New Zealand	
BG	Bulgaria	IT	Italy	PL	Poland	
BJ	Benin	JP	Japan	PT	Portugal	
BR	Brazil	KE	Kenya	RO	Romania	
BY	Belarus	KG	Kyrgystan	RU	Russian Federation	
CA	Canada	KP	Democratic People's Republic	SD	Sudan	
CF	Central African Republic		of Korea	SE	Sweden	
CG	Congo	KR	Republic of Korea	SG	Singapore	
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia	
CI	Côte d'Ivoire	u	Liechtenstein	SK	Slovakia	
CM	Cameroon	LK	Sri Lanka	SN	Senegal	
CN	China	LR	Liberia	SZ	Swaziland	
CS	Czechoslovakia	LT	Lithuania	TD	Chad	
CZ	Czech Republic	LU	Luxembourg	TG	Togo	
DE	Germany	LV	Latvia	TJ	Tajikistan	
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago	
EE	Estonia	MD	Republic of Moldova	UA	Ukraine	
ES	Spain	MG	Madagascar	UG	Uganda	
FI	Finland	ML	Mali	US	United States of America	
FR	France	MN	Mongolia	UZ	Uzbekistan	
GA	Gabon	MR	Mauritania	VN	Viet Nam	

COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS

5

10

15

FIELD OF THE INVENTION

This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to co-administration of an inhibitor of cyclooxygenase-2 and a leukotriene B4 receptor antagonist for treating inflammation and inflammation-related disorders, such as arthritis.

BACKGROUND OF THE INVENTION

Prostaglandins play a major role in the inflammation process, and the inhibition of prostaglandin production, especially production of 20 PGG2, PGH2 and PGE2, has been a common target of antiinflammatory drug discovery. However, common nonsteroidal antiinflammatory drugs (NSAIDs) that are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process are 25 also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAIDs can produce severe side effects, including life threatening ulcers, that limit their therapeutic 30 potential. An alternative to NSAIDs is the use of corticosteroids, which have even more drastic side effects, especially when long term therapy is involved.

Previous NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway including the enzyme cyclooxygenase (COX). The recent discovery of an inducible enzyme associated with inflammation (named "cyclooxygenase-2 (COX-2)" or "prostaglandin G/H synthase II") provides a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects.

In another portion of the arachidonic acid pathway, physiologically active leukotrienes, such as leukotriene B4 (LTB4), leukotriene C4 (LTC4) and

10 leukotriene D4 (LTD4) and other metabolites, are produced by the 5-lipoxygenase-mediated (5-LO) oxidation of arachidonic acid. These leukotrienes have been implicated in various inflammation-related disorders and allergic diseases, and thus compounds

15 which inhibit leukotriene A4 conversion to leukotriene B4, such as compounds which inhibit leukotriene A4 hydrolase are useful in the treatment of disease states in which leukotrienes play an important role.

It is believed that selective inhibitors of

20 cyclooxygenase-2 and of leukotriene A₄ hydrolase, which affect the two enzymes at low concentrations, will decrease the incidence and severity more completely. These compositions also will beneficially affect the damage caused by the various inflammatory diseases and inflammation-related disorders mediated by cyclooxygenase-2 and leukotriene A₄ hydrolase. These compositions also will not have the level of gastrointestinal side effects commonly associated with traditional NSATDs.

30 Compounds which selectively inhibit cyclooxygenase-2 have been described in U.S. patents 5,380,738, 5,344,991, 5,393,790, 5,466,823, 5,434,178, 5,474,995, 5,510,368 and WO documents W096/06840, W096/03388, W096/03387, W095/15316, W094/15932, 35 W094/27980, W095/00501, W094/13635, W094/20480, and W094/26731.

Compounds which affect leukotriene B4 have been described. U.S. Patent No. 5,384,318 describes substituted sulfonamides for the treatment of asthma. U.S. patent No. 5,246,965 describes arvl ethers as leukotriene B4 receptor antagonists.

Combined therapies of NSAIDs and other reagents are known in the art. Brooks and Karl describe the treatment of hay fever with combined antihistamines and a cyclooxygenase-inhibiting drug (flurbiprofen) 10 (J. Allergy Clin. Immunol., 81, 110 (1988)). J. Basmajian (Spine, 14, 438 (1989)) describes the combination of the analgesic diflunisal and an antispasm agent in the treatment of back pain. V. Fossaluzza and S. DeVita describe the combined therapy 15 of ibuprofen and an antispasm agent to reduce morning stiffness associated with primary fibromyaglia syndrome (Int. J. Clin. Pharm. Res., XII, 99 (1992)). R. Greenwald et al. (J. Rheumatol., 19, 927 (1992)) report the combination of tetracycline and the NSAID 20 flurbiprofen ameliorates the tissue damage associated with rheumatoid arthritis.

Combination analgesics have been reported (W. Beaver, Am. J. Med., 77, 38 (1984)) although such combinations do not substantially reduce adverse effects.

25

35

The combination of NSAIDs and steroids have been described. A combination of indomethacin, steroid and lipopolysaccharide has been reported for the treatment of spinal injury (L. Guth et al., Proc. Natl. Acad. Sci. USA, 91, 12308 (1994)). G. Hughes et al. describe combinations of corticosteroids with NSAIDs for the treatment of sunburn (Dermatology, 184, 54 (1992)). C. Stewart et al. (Clin. Pharmacol. Ther., 47, 540 (1990)) describe the combination of naproxen and methotrexate as safe, although concurrent administrations of methotrexate with other NSAIDs have been reported to be toxic and sometimes fatal. A

combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor with a glucocorticoid is described for the treatment of skin disorders (K. Tramposch, Inflammation, 17, 531 (1993)). Combinations of NSAIDs and steroids should be used in the treatment of scleritis only if patients are not responsive to any other treatment (S. Lightman and P. Watson, Am. J. Ophthalmol.. 108. 95 (1989)).

Combinations of cyclooxygenase inhibitors,

10 lipoxygenase inhibitors, collagenase inhibitors and
cytotoxic agents have been used in the treatment of
non-small-cell lung cancers (B. Teicher et al.,
Cancer. Chemother. Pharmacol., 33, 515 (1994)).

Combinations of naproxen with other NSAIDs have

been described in the treatment of arthritis. R. Willikens and E. Segre (Arthritis Rheum., 19, 677 (1976)) describe the combination of aspirin and naproxen as being more effective than aspirin alone for the treatment of rheumatoid arthritis. Naproxen

and acetaminophen together were described for treating the pain associated with arthritis (P. Seideman et al., Acta Orthop. Scand., 64, 285 (1993)). However, combinations of naproxen with indomethacin or ibuprofen offer no advantage in the treatment of arthritis [M. Seifert and C. Engler (Curr. Med. Res.

Opin., 7, 38 (1980))]. European patent document EP485,111, published May 13, 1992, describes the synergistic combination of lipoxygenase inhibitors and NSAID's for the treatment of inflammatory disease.

30 There have been no reported combinations of a cyclooxygenase-2 selective inhibitor and a leukotriene B_A receptor antagonist.

DESCRIPTION OF THE INVENTION

35


The invention involves a method of treating a subject having inflammation or an inflammation-related

PCT/US96/09905

WO 96/41645 5

disorder with a combination comprising a therapeutically-effective amount of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist.

5 In addition, the invention describes a combination comprising a therapeutically-effective amount of a leukotriene B4 receptor antagonist and a cyclooxygenase-2 inhibitor selected from Taisho NS-398, meloxicam, floculide, Merck MK-966, Merck L-752,860 and compounds of Formula I 1.0



wherein A is a substituent selected from 15 partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings:

wherein R1 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, 20 wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; 25

wherein R2 is methyl or amino; and wherein R3 is a radical selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cvanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl,

3.0

35

c

alkoxycarbonylalkyl, aminocarbonyl,
aminocarbonylalkyl, alkylaminocarbonyl, Narylaminocarbonyl, N-alkyl-N-arylaminocarbonyl,
alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, Narylamino, N-aralkylamino, N-alkyl-N-aralkylamino, Nalkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, Narylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-Naralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy,
aralkoxy, arylthio, aralkylthio, alkylsulfinyl,
alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, Narylaminosulfonyl, arylsulfonyl, N-alkyl-Narylaminosulfonyl; or a pharmaceutically-acceptable
salt thereof.
Combinations of the invention would be useful
for, but not limited to, the treatment of inflammation
in a subject, and for treatment of other inflammation

15 for, but not limited to, the treatment of inflammation in a subject, and for treatment of other inflammationassociated disorders, such as, as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever. For example, combinations 20 of the invention would be useful to treat arthritis, including but not limited to rheumatoid arthritis, spondyloarthopathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis. Such combinations of the invention would be useful in the treatment of asthma, bronchitis, menstrual cramps, 25 tendinitis, bursitis, and skin related conditions such as psoriasis, eczema, burns and dermatitis Combinations of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable 30 bowel syndrome and ulcerative colitis and for the prevention or treatment of cancer, such as colorectal cancer. Combinations of the invention would be useful in treating inflammation in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes,

myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, swelling occurring after injury, myocardial ischemia, and the like. The compounds would also be useful in the treatment of ophthalmic diseases, such as retinitis, retinopathies, conjunctivitis, uveitis, ocular photophobia, and of acute injury to the eve tissue. The compounds would also be useful in the treatment of pulmonary inflammation, such as that associated with viral infections and cystic fibrosis. The compounds would also be useful for the treatment of certain central nervous system disorders such as cortical dementias including Alzheimer's disease. The combinations of the invention are useful as anti-inflammatory agents. such as for the treatment of arthritis, with the

10

30

35

15 additional benefit of having significantly less harmful side effects. As inhibitors of 5lipoxygenase, these compositions would also be useful

20 in the treatment of allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome. atherosclerosis and central nervous system damage resulting from stroke, ischemia and trauma.

Besides being useful for human treatment, these 25 compounds are also useful for treatment of mammals, including horses, dogs, cats, rats, mice, sheep, pigs, etc.

The term "cyclooxygenase-2 inhibitor" embraces compounds which selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Preferably, the compounds have a cyclooxygenase-2 IC50 of less than about 0.5 µM, and also have a selectivity ratio of cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least 50, and more preferably of at least 100. Even more preferably, the compounds have a cyclooxygenase-1 IC_{50} of greater than about 1 μM , and more preferably of greater than 20 µM. Such preferred selectivity may

15

indicate an ability to reduce the incidence of common NSAID-induced side effects.

The term *leukotriene B_4 receptor antagonist" embraces compounds which selectively antagonize a leukotriene B_4 receptor with an IC $_{50}$ of less than about 10 μ M. More preferably, the leukotriene B_4 receptor antagonists have an IC $_{50}$ of less than about 1 μ M.

The phrase "combination therapy", "co-administration" or "co-therapy", in defining use of a cyclooxygenase-2 inhibitor agent and a leukotriene \mathbb{B}_4 receptor antagonist agent, are intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in

The phrase "therapeutically-effective" is

intended to qualify the amount of each agent for use
in the combination therapy which will achieve the goal
of improvement in inflammation severity and the
frequency of incidence over treatment of each agent by
itself, while avoiding adverse side effects typically
associated with alternative therapies.

multiple, separate capsules for each agent.

Preferred leukotriene B4 receptor antagonists include Bayer Bay-x-1005, Ciba-Geigy CGS-25019C, ebselen, Leo Denmark ETH-615, Lilly LY-293111, Ono ONO-4057, Terumo TMK-688, Boehringer Ingleheim BI-RM-30 270, Lilly LY 213024, Lilly LY 264086, Lilly LY 292728, Ono ONO LB457, Pfizer 105696, Perdue Frederick PF 10042, Rhone-Foulenc Rorer RP 66153, SmithKline Beecham SB-201146, SmithKline Beecham SB-201993, Searle SC-53228, Sumitamo SM 15178, American Home Products WAY 121006, Bayer Bay-o-8276, calcitriol, Warner-Lambert CI-987, Merck and Co. L-651392, Lilly LY 210073, Lilly LY 223982, Lilly LY 233559, Lilly LY

255283, Merck and Co. MK-591, Merck and Co. MK-886, Ono ONO-LB-448, Purdue Frederick PF-5901, Rhone-Poulenc Rorer RG 14893, Rhone-Poulenc Rorer RP 66364, Rhone-Poulenc Rorer RP 69698, Searle SC-41930, Searle 5 SC-50505, Searle SC-51146, SmithKline Beecham SK&F-104493, and Teijin TEI-1338.

More preferred leukotriene B4 receptor antagonists include Bayer Bay-x-1005, Ciba-Geigy CGS-25019C, ebselen, Leo Denmark ETH-615, Lilly LY-293111, 10 Ono ONO-4057, Terumo TMK-688, Boehringer Ingleheim BI-RM-270, Lilly LY 213024, Lilly LY 264086, Lilly LY 292728, Ono ONO LB457, Pfizer 105696, Perdue Frederick PF 10042, Rhone-Poulenc Rorer RP 66153, SmithKline Beecham SB-201146, SmithKline Beecham SB-201993.

Searle SC-53228, Sumitamo SM 15178, and American Home 1.5 Products WAY 121006.

20

Even more preferred leukotriene B4 receptor antagonists include Bayer Bay-x-1005, Ciba-Geigy CGS-25019C, ebselen, Leo Denmark ETH-615, Lilly LY-293111, Ono ONO-4057, and Terumo TMK-688.

A preferred class of compounds which inhibit cyclooxygenase-2 consists of compounds of Formula I wherein A is selected from 5- or 6-member partially unsaturated heterocyclyl, 5- or 6-member unsaturated heterocyclyl, 9- or 10-member unsaturated condensed heterocyclyl, lower cycloalkenyl and phenyl; wherein R1 is selected from 5- and 6-membered heterocyclyl, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio; wherein R2 is methyl or

amino; and wherein R3 is a radical selected from

hydrido, oxo, cvano, carboxyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, halo, lower alkyl, lower alkyloxy, lower cycloalkyl, phenyl, lower haloalkyl, 5- or 6-membered heterocyclyl, lower 5 hydroxylalkyl, lower aralkyl, acyl, phenylcarbonyl, lower alkoxyalkyl, 5- or 6-membered heteroaryloxy, aminocarbonyl, lower alkylaminocarbonyl, lower alkylamino, lower aminoalkyl, lower alkylaminoalkyl, phenyloxy, and lower aralkoxy; or a pharmaceuticallyacceptable salt thereof.

A more preferred class of compounds which inhibit

cyclooxygenase-2 consists of compounds of Formula I wherein A is selected from oxazolyl, isoxazolyl, thienyl, dihydrofuryl, furyl, pyrrolyl, pyrazolyl, 15 thiazolyl, imidazolyl, isothiazolyl, benzofuryl, cyclopentenyl, cyclopentadienyl, phenyl, and pyridyl; wherein R1 is selected from pyridyl optionally substituted at a substitutable position with one or more methyl radicals, and phenyl optionally substituted 20 at a substitutable position with one or more radicals selected from methyl, ethyl, isopropyl, butyl, tertbutyl, isobutyl, pentyl, hexyl, cyano, fluoromethyl, difluoromethyl, trifluoromethyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, hydroxymethyl, 25 trifluoromethoxy, hydroxyl, amino, N-methylamino, N,Ndimethylamino, N-ethylamino, N,N-dipropylamino, Nbutylamino, N-methyl-N-ethylamino, phenylamino, methoxymethyl, methylsulfinyl, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, and 30 methylthio; wherein R2 is methyl or amino; and wherein R3 is a radical selected from hydrido, oxo, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, carboxypropyl, carboxymethyl, carboxyethyl, cvanomethyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl. difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, difluoroethyl, difluoropropyl,

20

30

methoxy, ethoxy, propoxy, n-butoxy, pentoxy, cyclohexyl, phenyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, pyrazinyl, hydroxylmethyl, hydroxylpropyl, benzyl, formyl, phenylcarbonyl, 5 methoxymethyl, furylmethyloxy, aminocarbonyl, Nmethylaminocarbonyl, N.N-dimethylaminocarbonyl, N.Ndimethylamino, N-ethylamino, N,N-dipropylamino, Nbutylamino, N-methyl-N-ethylamino, aminomethyl, N,Ndimethylaminomethyl, N-methyl-N-ethylaminomethyl, benzyloxy, and phenyloxy; or a pharmaceuticallyacceptable salt thereof.

A family of specific compounds of particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts thereof as follows:

- 5-(4-fluorophenvl)-1-[4-(methylsulfonvl)phenvl]-3-15 (trifluoromethyl)pyrazole;
 - 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1pheny1-3-(trifluoromethyl)pyrazole;
 - 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide
 - 4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1vl)benzenesulfonamide:
 - 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-
- yl)benzenesulfonamide; 25 4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1vl)benzenesulfonamide;
 - 4-(5-(4-chlorophenvl)-3-(4-methylphenvl)-1H-pyrazol-1yl)benzenesulfonamide;
 - 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1yl)benzenesulfonamide;
 - 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1Hpyrazol-1-v1)benzenesulfonamide;
 - 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1vl)benzenesulfonamide
- 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-35 1-vllbenzenesulfonamide;

- 4-[5-pheny1-3-(trifluoromethy1)-1H-pyrazol-1yl]benzenesulfonamide;
- 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide;
- 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide;
 - 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1vllbenzenesulfonamide:
 - 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-vllbenzenesulfonamide:
 - 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl]benzenesulfonamide;
 - 4-[3-(difluoromethy1)-5-(4-methylpheny1)-1H-pyrazol-1vllbenzenesulfonamide;
- 15 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1yl]benzenesulfonamide;
 - 4-[3-(difluoromethy1)-5-(4-methoxypheny1)-1H-pyrazol-1-yl]benzenesulfonamide;
 - 4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1yl]benzenesulfonamide;
 - 4-[3-(difluoromethy1)-5-(3-fluoro-4-methoxypheny1)-1Hpyrazol-1-yl]benzenesulfonamide;
 - 4-[5-(3-fluoro-4-methoxypheny1)-3-(trifluoromethy1)-1H-pyrazol-1-vl|benzenesulfonamide:
- 25 4-[4-chloro-5-phenvl-1H-pvrazo]-1vllbenzenesulfonamide;

10

20

- 4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1vllbenzenesulfonamide:
- 4-[5-(4-(N,N-dimethylamino)phenyl)-3-
- 30 (trifluoromethyl)-1H-pyrazol-1
 - vllbenzenesulfonamide:
 - 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
 - 4-[6-(4-fluorophenyl)spiro[2.4]hept-5-en-5-
- 35 vllbenzenesulfonamide;
 - 6-(4-fluorophenvl)-7-[4-(methylsulfonyl)phenyl]spiro[3.4]oct-6-ene;

20

13

- 5-(3-chloro-4-methoxyphenyl)-6-[4(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
- 4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5yl]benzenesulfonamide;
- 5 5-(3,5-dichloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
 - 5-(3-chloro-4-fluorophenyl)-6-[4(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
 - 4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5v1]benzenesulfonamide;
 - 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4methylsulfonylphenyl)thiazole;
 - 2-(2-chloropheny1)-4-(4-fluoropheny1)-5-(4methylsulfonylphenyl)thiazole;
- 15 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2methylthiazole;
 - 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2trifluoromethylthiazole;
 - 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2thienyl)thiazole;
 - 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2benzylaminothiazole;
 - 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1propylamino)thiazole;
- 25 2-[(3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-[(4-(methylsulfonyl)phenyl]thiazole;
 - 5-(4-fluoropheny1)-4-(4-methylsulfonylpheny1)-2trifluoromethylthiazole;
 - 1-methylsulfonyl-4-[1,1-dimethyl-4-(4-
- 30 fluorophenyl)cyclopenta-2,4-dien-3-yl]benzene;
 - 4-[4-(4-fluorophenyl)-1,1-dimethylcyclopenta-2,4-dien-3-yl]benzenesulfonamide;
 - 5-(4-fluorophenyl)-6-[4 (methylsulfonyl)phenyl]spiro[2.4]hepta-4,6-diene;
- 35 4-[6-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-5yl]benzenesulfonamide;

WO 96/41645 PCT/US96/09905

```
14
    6-(4-fluorophenvl)-2-methoxv-5-[4-
       (methylsulfonyl)phenyl]-pyridine-3-carbonitrile;
    2-bromo-6-(4-fluorophenvl)-5-[4-
       (methylsulfonyl)phenyl]-pyridine-3-carbonitrile;
    6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-
       phenyl-pyridine-3-carbonitrile;
    4-[2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-
       imidazol-1-vllbenzenesulfonamide:
    4-[2-(5-methylpyridin-3-v1)-4-(trifluoromethyl)-1H-
10
       imidazol-1-yl]benzenesulfonamide;
    4-[2-(2-methylpyridin-3-vl)-4-(trifluoromethyl)-1H-
       imidazol-1-yl]benzenesulfonamide;
    3-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-
       1H-imidazol-2-vllpvridine:
15
    2-[1-[4-(methy]sulfonyl)phenyl-4-(trifluoromethyl)-1H-
       imidazol-2-vl]pyridine;
    2-methyl-4-[1-[4-(methylsulfonyl)phenyl-4-
       (trifluoromethyl)-1H-imidazol-2-vl]pvridine;
    2-methyl-6-[1-[4-(methylsulfonyl)phenyl-4-
20
       (trifluoromethyl)-1H-imidazol-2-vllpvridine;
    4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-
       imidazol-1-yl]benzenesulfonamide;
    2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-
       (trifluoromethyl)-1H-imidazole:
25
    4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-
       1-vllbenzenesulfonamide:
    2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-
       methyl-1H-imidazole;
    2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-
30
       phenyl-1H-imidazole;
    2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[4-
       (methylsulfonyl)phenyl]-1H-imidazole;
    2-(3-fluoro-4-methoxyphenyl)-1-[4-
       (methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-
```

35

imidazole:

1-[4-(methylsulfonyl)phenyl]-2-phenyl-4trifluoromethyl-1H-imidazole;

- 2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4trifluoromethyl-1H-imidazole;
- 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1Himidazol-1-v1]benzenesulfonamide;
- - 4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1Himidazol-1-yl]benzenesulfonamide;
- 10 2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4trifluoromethyl-1H-imidazole;
 - 4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1yl]benzenesulfonamide;
 - 1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4trifluoromethyl-1H-imidazole;
 - 4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1vl]benzenesulfonamide;
 - 4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1v1]benzenesulfonamide;
- 20 4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1Himidazol-1-yl]benzenesulfonamide;
 - 1-allyl-4-(4-fluorophenyl)-3-[4 (methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H pyrazole;
- 25 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1Hpyrazol-3-yl]benzenesulfonamide;
 - N-pheny1-[4-(4-luoropheny1)-3-[4(methylsulfony1)phenyl]-5-(trifluoromethy1)-1Hpyrazol-1-yl]acetamide;
- - 4-(4-fluoropheny1)-3-[4-(methylsulfony1)pheny1]-1-(2phenylethyl)-1H-pyrazole;
- 35 4-(4-fluoropheny1)-3-[4-(methylsulfony1)pheny1]-1-(2phenylethy1)-5-(trifluoromethy1)pyrazole;

PCT/US96/09905 WO 96/41645

```
16
    1-ethyl-4-(4-fluorophenyl)-3-[4-
       (methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-
       pyrazole:
    5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-
 5
       trifluoromethyl-1H-imidazole;
    4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-
       (trifluoromethyl)-1H-imidazole;
    5-(4-fluorophenyl)-2-methoxy-4-[4-
       (methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
10
    2-ethoxy-5-(4-fluorophenvl)-4-[4-
       (methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
    5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-(2-
       propynyloxy)-6-(trifluoromethyl)pyridine;
    2-bromo-5-(4-fluorophenyl)-4-[4-
15
       (methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
    4-[2-(3-chloro-4-methoxyphenyl)-4,5-
       difluorophenyl]benzenesulfonamide:
    1-(4-fluorophenv1)-2-[4-
       (methylsulfonyl)phenyl]benzene;
20
    5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-
       phenvlisoxazole:
    4-[3-ethyl-5-phenylisoxazol-4-vl]benzenesulfonamide:
    4-[5-difluoromethyl-3-phenylisoxazol-4-
       yl]benzenesulfonamide;
25
   4-[5-hydroxymethyl-3-phenylisoxazol-4-
       vllbenzenesulfonamide:
    4-[5-methyl-3-phenyl-isoxazol-4-v1]benzenesulfonamide;
    1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-
       (methylsulfonyl)benzene;
3.0
    1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-
       (methylsulfonyl)benzene;
    1-[2-(4-chlorophenyl)cyclopenten-1-v1]-4-
       (methylsulfonvl)benzene:
    1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-
```

1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-

35

(methylsulfonvl)benzene:

(methylsulfonyl)benzene;

PCT/US96/09905 WO 96/41645

17

1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;

- 1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1vl]benzenesulfonamide;
 - 1-[2-(4-chlorophenyl)-4.4-dimethylcyclopenten-1-vl]-4-(methylsulfonyl)benzene;
 - 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1vl]benzenesulfonamide;
 - 4-[2-(4-fluorophenyl)cyclopenten-1-
 - yl]benzenesulfonamide;
 - 4-[2-(4-chlorophenyl)cyclopenten-1
 - yl]benzenesulfonamide;

10

- 15 1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - 1-[2-(2,3-difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonvl)benzene:
 - 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-
- 20 vllbenzenesulfonamide;
 - 1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - 4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1yl]benzenesulfonamide:
- 25 4-[2-(2-methylpyridin-5-vl)cyclopenten-1yl]benzenesulfonamide;
 - ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl) phenyl]oxazo1-2-yl]-2-benzyl-acetate;
 - 2-[4-(4-fluorophenyl)-5-[4-
- 30 (methylsulfonyl)phenylloxazol-2-yllacetic acid;
 - 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
 - 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2phenyloxazole;
- 4-(4-fluoropheny1)-2-methy1-5-[4-35 (methylsulfonyl)phenyl]oxazole; and

4-[5-(3-fluoro-4-methoxypheny1)-2-trifluoromethy1-4-oxazolyl]benzenesulfonamide.

The term "hydrido" denotes a single hydrogen atom 5 (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH2-) radical. Where used, either alone or within other terms such as "haloalkyl", "alkvlsulfonyl", "alkoxyalkyl" and "hydroxyalkyl", the 10 term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about 15 ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, npropyl, isopropyl, n-butyl, isobutyl, sec-butyl, tertbutyl, pentyl, iso-amyl, hexyl and the like. The term "alkenyl" embraces linear or branched radicals having 20 at least one carbon-carbon double bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkyl radicals are "lower alkenvl" radicals having two to about six carbon atoms. 25 Examples of alkenyl radicals include ethenyl, propenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The term "alkynyl" denotes linear or branched radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to 30 about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms. Examples of such radicals include propargyl, butynyl, and the like. The terms "alkenvl", "lower alkenvl", embrace radicals having "cis" and "trans" orientations. or alternatively, "E" and "Z" orientations. The term "cycloalkyl" embraces saturated carbocyclic radicals

having three to twelve carbon atoms. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkenyl" embraces partially unsaturated carbocyclic radicals having three to twelve carbon atoms. More preferred cycloalkenyl radicals are "lower cycloalkenyl" radicals having four to about eight carbon atoms. Examples of 10 such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl and cyclohexenyl. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is 15 substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and 20 polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having 1-6 carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, 25 chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term "hydroxyalkyl" embraces 30 linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals 35

include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms "alkoxy" and

"alkyloxy" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term "alkoxyalkyl" embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl 10 radicals. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. More preferred haloalkoxy radicals are "lower haloalkoxy" radicals having one to six carbon 15 atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy. The term "aryl", alone or in combination, means a carbocyclic aromatic system 20 containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenvl. Arvl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl. alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, 3.0 acyl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl. The term "heterocyclo" embraces saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, where the heteroatoms may be selected from nitrogen, sulfur and 35 oxygen. Examples of saturated heterocyclo radicals include saturated 3 to 6-membered heteromonocylic

group containing 1 to 4 nitrogen atoms (e.g.

pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclo radicals include dihydrothiophene, dihydropyran, dihydrofuran and 10 dihydrothiazole. The term "heteroaryl" embraces unsaturated heterocyclo radicals. Examples of unsaturated heterocyclo radicals, also termed "heteroaryl" radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, 15 imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g. 1H-tetrazolvl, 2H-tetrazolvl, etc.), etc.; unsaturated condensed heterocyclo group containing 1 20 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 25 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclo group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl, 35 benzoxadiazolyl, etc.); unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms

and 1 to 3 nitrogen atoms, for example, thiazolvl. thiadiazolyl (e.g., 1,2,4- thiadiazolyl, 1,3,4thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclo group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term also embraces radicals where heterocyclo radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said "heterocyclo group" may have 1 to 3 substituents such as alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino. The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to about ten 15 carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and 20 hexylthio. The term "alkylthioalkyl" embraces radicals containing an alkylthic radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkyl radicals are "lower alkylthioalkyl" 25 radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkyl radicals include methylthiomethyl. The term "alkylsulfinyl" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent -S(=0) - radical. More preferred alkylsulfinyl radicals are "lower alkylsulfinyl" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term "sulfonyl", whether used 35 alone or linked to other terms such as alkylsulfonyl. denotes respectively divalent radicals -SO2-.

"Alkylsulfonyl" embraces alkyl radicals attached to a sulfonvl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl" radicals having one to six carbon 5 atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The terms "sulfamyl", 10 "aminosulfonyl" and "sulfonamidyl" denote NH2O2S-. The term "acyl" denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl 15 and aroyl radicals. Examples of such lower alkanovl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl. The term "carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", denotes - (C=O) -. The term "aroyl" embraces aryl 20 radicals with a carbonyl radical as defined above. Examples of aroyl include benzoyl, naphthoyl, and the like and the arvl in said arovl may be additionally substituted. The terms "carboxy" or "carboxyl". 25 whether used alone or with other terms, such as "carboxyalkyl", denotes -CO2H. The term "carboxyalkyl" embraces alkyl radicals substituted with a carboxy radical. More preferred are "lower carboxvalkvl" which embrace lower alkvl radicals as defined above, and may be additionally substituted on 30 the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. More preferred are "lower

alkoxycarbonyl" radicals with alkyl porions having 1

to 6 carbons. Examples of such lower alkoxycarbonyl (ester) radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The terms "alkylcarbonyl", "arylcarbonyl" and "aralkylcarbonyl" include radicals having alkyl, aryl and aralkyl radicals, as defined above, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted methylcarbonyl, 10 ethylcarbonyl, phenylcarbonyl and benzylcarbonyl. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be additionally substituted 15 with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The terms benzyl and phenylmethyl are interchangeable. The term "heterocycloalkyl" embraces saturated and partially unsaturated heterocyclo-substituted alkyl radicals, such as pyrrolidinylmethyl, and heteroaryl-20 substituted alkyl radicals, such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The term 25 "aralkoxy" embraces aralkyl radicals attached through an oxygen atom to other radicals. The term "aralkoxyalkyl" embraces aralkoxy radicals attached through an oxygen atom to an alkyl radical. The term "aralkylthio" embraces aralkyl radicals attached to a 30 sulfur atom. The term "aralkylthioalkyl" embraces aralkylthic radicals attached through a sulfur atom to an alkyl radical. The term "aminoalkyl" embraces alkyl radicals substituted with one or more amino radicals. More preferred are "lower aminoalkyl" radicals. Examples of such radicals include 35 aminomethyl, aminoethyl, and the like. The term

"alkylamino" denotes amino groups which have been

substituted with one or two alkyl radicals. Preferred are "lower N-alkylamino" radicals having alkyl portions having 1 to 6 carbon atoms. Suitable lower alkylamino may be mono or dialkylamino such as Nmethylamino, N-ethylamino, N,N-dimethylamino, N,Ndiethylamino or the like. The term "arylamino" denotes amino groups which have been substituted with one or two aryl radicals, such as N-phenylamino. The "arylamino" radicals may be further substituted on the 10 aryl ring portion of the radical. The term "aralkylamino" embraces aralkyl radicals attached through an amino nitrogen atom to other radicals. The terms "N-arylaminoalkyl" and "N-aryl-N-alkylaminoalkyl" denote amino groups which have been substituted with one aryl radical or one aryl and one 15 alkyl radical, respectively, and having the amino group attached to an alkyl radical. Examples of such radicals include N-phenylaminomethyl and N-phenyl-Nmethylaminomethyl. The term "aminocarbonyl" denotes 20 an amide group of the formula -C(=O)NH2. The term "alkylaminocarbonyl" denotes an aminocarbonyl group which has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are "N-alkylaminocarbonyl" "N,N-dialkylaminocarbonyl" 25 radicals. More preferred are "lower Nalkylaminocarbonyl" "lower N.N-dialkylaminocarbonyl" radicals with lower alkyl portions as defined above. The term "alkylaminoalkyl" embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical. The term "aryloxyalkyl" embraces radicals having an aryl radical attached to an alkyl radical through a divalent oxygen atom. The term "arvlthioalkyl" embraces radicals having an aryl radical attached to an alkyl radical through a 35 divalent sulfur atom.

The present invention comprises a pharmaceutical composition comprising a therapeutically-effective

amount of a leukotriene B_4 receptor antagonist and of a cyclooxygenase-2 inhibitor compound in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

The present invention also comprises a method of treating inflammation or inflammation-associated disorders in a subject, the method comprising administering to the subject having or susceptible to such inflammation or disorder a therapeutically10 effective amount of a leukotriene B4 receptor antagonist and of a cyclooxygenase-2 inhibitor. The method of the present invention also includes prophylactic or chronic treatment, especially in the case of arthritis and other inflammatory conditions
15 which can lead to deterioration in the joints.

Also included in the family of compounds of Formula I are the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts 20 and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be prepared from an 25 inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic. hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, 30 heterocyclo, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, p-35 hydroxybenzoic, phenylacetic, mandelic, embonic

(pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-

hydroxyethanesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic, β-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I.

GENERAL SYNTHETIC PROCEDURES

The cyclooxygenase-2 inhibitor compounds of the invention can be synthesized according to the 20 following procedures of Schemes I-X, wherein the R¹-R³ substituents are as defined for Formula I, above, except where further noted.

Scheme I

Synthetic Scheme I shows the preparation of cyclooxygenase-2 inhibitor compounds, as described in U.S. patent No. 5,466,823, embraced by Formula I where R is Ar or Z (as defined in Scheme I), and Ra is a radical defined above for the substituents optionally substituted on A. In step 1, ketone 1 is treated with a base, preferably NaOMe or NaH, and an ester, or 10 ester equivalent, to form the intermediate diketone 2 (in the enol form) which is used without further purification. In step 2, diketone 2 in an anhydrous protic solvent, such as absolute ethanol or acetic 15 acid, is treated with the hydrochloride salt or the free base of a substituted hydrazine at reflux to afford a mixture of pyrazoles 3 and 4.

Recrystallization or chromatography affords 3 usually as a solid. Similar pyrazoles can be prepared by methods described in U.S. Pat. Nos. 4,146,721, 5.051.518, 5.134.142 and 4.914.121.

Scheme II

Scheme II shows the four step procedure for

forming cyclooxygenase-2 inhibitor pyrazoles 8 as 10 described in U.S. patent No. 5,486,534 (where Ra is alkvl) from ketones 5. In step 1, ketone 5 is reacted with a base, such as lithium bis(trimethylsilyl)amide or lithium diisopropylamide (LDA) to form the anion. In step 2, the anion is reacted with an acetylating 15 reagent to provide diketone 6. In step 3, the reaction of diketone 6 with hydrazine or a substituted hydrazine, gives pyrazole 7. In step 4, the pyrazole 7 is oxidized with an oxidizing reagent, such as 20 Oxone® (potassium peroxymonosulfate), 3chloroperbenzoic acid (MCPBA) or hydrogen peroxide, to give a mixture of the desired 3-(alkylsulfonyl)phenylpyrazole 8 and the 5-(alkylsulfonyl)phenyl-pyrazole isomer. The desired pyrazole 8, usually a white or pale yellow solid, is obtained in pure form either by 25 chromatography or recrystallization.

3,984,431.

Alternatively, diketone 6 can be formed from ketone 5 by treatment with a base, such as sodium hydride, in a solvent, such as dimethylformamide, and further reacting with a nitrile to form an aminoketone. Treatment of the aminoketone with acid forms the diketone 6. Similar pyrazoles can be prepared by methods described in U.S. Pat. No.

Scheme III

5 Cyclooxygenase-2 inhibitor diaryl/heteroaryl thiophenes (where T is S, and R^b is alkyl) can be prepared by the methods described in U.S. Patent Nos. 4,427,693, 4,302,461, 4,381,311, 4,590,205, and 4,820,827, and PCT documents WO 95/00501 and WO94/15932. Similar pyrroles (where T is N), furanones and furans (where T is O) can be prepared by

methods described in PCT documents WO 95/00501 and WO94/15932.

Scheme IV

5

Cyclooxygenase-2 inhibitor diaryl/heteroaryl oxazoles can be prepared by the methods described in 10 U.S. Patent Nos. 3,743,656, 3,644,499 and 3,647,858, and PCT documents WO 95/00501 and WO94/27980.

Scheme V

5 Cyclooxygenase-2 inhibitor diaryl/heteroaryl isoxazoles can be prepared by the methods described in United States application Serial No. 08/387,680, PCT documents W092/05162, and W092/19604, and European Publication EP 26928. Sulfonamides 24 can be formed 10 from the hydrated isoxazole 23 in a two step procedure. First, hydrated isoxazole 23 is treated at about 0 °C with two or three equivalents of chlorosulfonic acid to form the corresponding sulfonyl chloride. In step two, the sulfonyl chloride thus 15 formed is treated with concentrated ammonia to provide the sulfonamide derivative 24.

Scheme VI

Scheme VI shows the three step preparation of the cyclooxygenase-2 inhibitor imidazoles 29 of the present invention. In step 1, the reaction of substituted nitriles (R1CN) 25 with primary phenylamines 26 in the presence of alkylaluminum reagents such as trimethylaluminum, triethylaluminum, 10 dimethylaluminum chloride, diethylaluminum chloride in the presence of inert solvents such as toluene, benzene, and xylene, gives amidines 27. In step 2, the reaction of amidine 27 with 2-haloketones (where X is Br or Cl) in the presence of bases, such as sodium bicarbonate, potassium carbonate, sodium carbonate, 15 potassium bicarbonate or hindered tertiary amines such as N,N'-diisopropylethylamine, gives the 4,5dihydroimidazoles 28 (where R^b is alkyl). Some of the suitable solvents for this reaction are isopropanol, acetone and dimethylformamide. The reaction may be carried out at temperatures of about 20°C to about 50°C. In step 3, the 4,5-dihydroimidazoles 28 may be dehydrated in the presence of an acid catalyst such as 4-toluenesulfonic acid or mineral acids to form the 1,2-disubstituted imidazoles 29 of the invention. Suitable solvents for this dehydration step are e.g., 10 toluene, xylene and benzene. Trifluoroacetic acid can be used as solvent and catalyst for this dehydration step.

In some cases (e.g., where YR = methyl or phenyl)
the intermediate 28 may not be readily isolable. The
reaction, under the conditions described above,
proceeds to give the targeted imidazoles directly.
Similarly, imidazoles can be prepared having the
sulfonylphenyl moiety attached at position 2 and R1
attached at the nitrogen atom at position 1.
Diaryl/heteroaryl imidazoles can be prepared by the
methods described in U.S. Patent Nos. 4,822,805, PCT

document WO 96/03388 and PCT document WO 93/14082.

Scheme VII

The subject imidazole cyclooxygenase-2 inhibitor compounds 36 of this invention may be synthesized according to the sequence outlined in Scheme VII.

Aldehyde 30 may be converted to the protected cyanohydrin 31 by reaction with a trialkylsilyl oyanide, such as trimethylsilyl cyanide (TMSCN) in the

presence of a catalyst such as zinc iodide (ZnI2) or potassium cvanide (KCN). Reaction of cvanohydrin 31 with a strong base followed by treatment with benzaldehyde 32 (where R2 is alkyl) and using both acid and base treatments, in that order, on workup gives benzoin 33. Examples of strong bases suitable for this reaction are lithium diisopropylamide (LDA) and lithium hexamethyldisilazane. Benzoin 33 may be converted to benzil 34 by reaction with a suitable oxidizing agent, such as bismuth oxide or manganese 10 dioxide, or by a Swern oxidation using dimethyl sulfoxide (DMSO) and trifluoroacetic anhydride. Benzil 34 may be obtained directly by reaction of the anion of cvanohydrin 31 with a substituted benzoic acid halide. Any of compounds 33 and 34 may be used as intermediates for conversion to imidazoles 35 (where R2 is alkvl) according to chemical procedures known by those skilled in the art and described by M. R. Grimmett, "Advances in Imidazole Chemistry" in Advances in Heterocyclic Chemistry, 12, 104 20 (1970). The conversion of 34 to imidazoles 35 is carried out by reaction with ammonium acetate and an appropriate aldehyde (RYCHO) in acetic acid. Benzoin 36 may be converted to imidazoles 38 by reaction with formamide. In addition, benzoin 36 may be converted 25 to imidazoles by first acylating with an appropriate acyl group (RYCO-) and then treating with ammonium hydroxide. Those skilled in the art will recognize that the oxidation of the sulfide (where R2 is methyl) to the sulfone may be carried out at any point along 30 the way beginning with compounds 35, and including oxidation of imidazoles 38, using, for examples, reagents such as hydrogen peroxide in acetic acid, mchloroperoxybenzoic acid (MCPBA) and potassium peroxymonosulfate (OXONE®). 35

Diaryl/heteroaryl imidazoles can be prepared by the methods described in U.S. Patent Nos. 3,707,475, 4,686,231, 4,503,065, 4,472,422, 4,372,964, 4,576,958, 3,901,908, PCT document WO 96/03387, 5 European publication EP 372,445, and PCT document WO 95/00501.

Scheme VIII

10

Diaryl/heteroaryl cyclopentene cyclooxygenase-2 inhibitors can be prepared by the methods described in

U.S. Patent No. 5,344,991, and PCT document WO 95/00501.

5

25

Scheme IX

SO₂R²

Br

+ R^LB (OH) 2

Pd⁰, PhCH₃,
C₂H₅OH,
Na₂CO₃, Δ

R³

R³

R³

44

Similarly, Synthetic Scheme IX shows the procedure for the preparation of 1,2-diarylbenzene cyclooxygenase-2 inhibitor agents 44 from 2-bromo-10 biphenyl intermediates 43 (prepared similar to that described in Synthetic Scheme VIII) and the appropriate substituted phenylboronic acids. Using a coupling procedure similar to the one developed by Suzuki et al. [Synth. Commun., 11, 513 (1981)], 15 intermediates 43 are reacted with the boronic acids in toluene/ethanol at reflux in the presence of a Pdo catalvst, e.g., tetrakis(triphenylphosphine)palladium(0), and 2M sodium carbonate to give the corresponding 1,2diarylbenzene antiinflammatory agents 44 of this invention. Such terphenyl compounds can be prepared by the methods described by J. Li et al., [J. Med. Chem., 39, 1846-56 (1996)].

25

Scheme X

$$R^{2} \xrightarrow{\overset{\circ}{\text{Br}}} O \xrightarrow{\text{Br}} H_{2}N \xrightarrow{\overset{\circ}{\text{H}}} R^{3} \xrightarrow{\text{CH}_{3}\text{CN}, \text{EtoH}} R^{2} \xrightarrow{\overset{\circ}{\text{R}^{2}}} \prod_{N} R^{3}$$

$$43 \qquad 46 \qquad \qquad 47$$

Diaryl/heteroaryl thiazole cyclooxygenase-2
inhibitors can be prepared by the methods described in
U.S. Patent No. 4,051,250, 4,632,930, PCT document WO
96/03392, European Application EP 592,664, and PCT
document WO 95/00501. Isothiazoles can be prepared as
described in PCT document WO 95/00501

10 Aryl/heteroaryl substituted pyridine cyclooxygenase-2 inhibitors can be prepared by the methods described in U.S. Patent Nos. 5,169,857, 4,011,328, 4,533,666, and W096/10012. Diaryl/heteroaryl benzofuran derivatives can be prepared by the methods described in W096/06840.

The following examples contain detailed descriptions of the methods of preparation of combinations with compounds of Formula I. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated. All compounds showed NMR spectra consistent with their assigned structures.

PCT/US96/09905 WO 96/41645

41

RIOLOGICAL EVALUATION

A combination therapy of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist could be evaluated as 5 described in the following tests.

Example 1

4-[5-(4-Chlorophenv1)-3-(trifluoromethv1)-1H-pyrazol-1-yl]benzenesulfonamide

Step 1: Preparation of 4,4,4-trifluoro-1-[4-(chloro)phenvl]butane-1.3-dione .

10

15

30

Ethyl trifluoroacetate (23.52 g, 166 mmol) was dissolved in methyl tert-butyl ether (75 mL). To the stirred solution was added 25 weight % sodium methoxide (40 mL, 177 mmol). Next 4'-chloroacetophenone (23.21 g, 150 mmol) was dissolved in methyl tert-butyl ether (20 mL), and added to the reaction dropwise. After stirring overnight (15.75 hours), 3N HCl (70 mL) was added. The organic layer was collected, washed with 20 brine (75 mL), dried over MgSO4, filtered, and concentrated in vacuo to give a 35.09 g of yellow-orange solid. The solid was recrystallized from isooctane to give 31.96 g (85%) of the dione: mp 66-67 °C.

Step 2: Preparation of 4-[5-(4-chlorophenv1)-3-25 (trifluoromethyl)-1H-pyrazol-1-yllbenzenesulfonamide.

4-Sulphonamidophenyl hydrazine hydrochloride (982 mg, 4.4 mmol) was added to a stirred solution of 4.4.4-trifluoro-1-[4-(chloro)phenyl]-butane-1,3-dione (1.00 g, 4.0 mmol) in ethanol (50 mL). The reaction was heated to reflux and stirred for 20 hours. After cooling to room temperature, the reaction mixture was concentrated in vacuo. The residue was taken up in ethyl acetate and washed with water and brine and dried over MgSO4, filtered, and concentrated in vacuo to give a light brown solid which was recrystallized from ethyl acetate and isooctane to give the pyrazole (1.28 g, 80%): mp 143-145 °C. EI GC-MS M+ = 401.

WO 96/41645 PCT/US96/09905

42

Example 2

4-[5-(3-Fluoro-4-methoxypheny1)-3-(difluoromethy1)-1Hpyrazol-1-yl] benzenesulfonamide

5 Step 1: Preparation of 3'-fluoro-4'-methoxy-acetophenone.

Acetyl chloride (51.0 g, 0.65 mol) was added dropwise to a stirred solution of aluminum chloride (80.0 g, 0.6 mol) and chloroform (750 mL), maintaining the temperature between 5-10°C. The mixture was stirred for 10 minutes at 5 °C before the dropwise addition of 2-fluoroanisole (62.6 g, 0.5 mol). The mixture was stirred at 0-10 °C for 1 hour and poured into ice (1 L). The resultant layers were separated and the aqueous layer was extracted with dichloromethane (2x250 mL). The combined organic layers were washed with water (2x150 15 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to a volume of 300 mL. Hexanes were added and a white solid formed which was isolated by filtration and air dried. This material was recrystallized from a mixture of dichloromethane and hexanes to afford (77.2 g, 92%) of material suitable for use in the next step: mp 92-94 °C. 2.0

Step 2: Preparation of 4.4-difluoro-1-(3-fluoro-4methoxyphenyl)-butane-1.3-dione.

Ethyl difluoroacetate (4.06 g, 32.7 mmol) was dissolved
in methyl t-butyl ether (50 mL). To the stirred solution was
added 25 weight % sodium methoxide (7.07 g, 32.7 mmol)
followed by 3'-fluoro-4'-methoxyacetophenone (5.0 g, 29.7
mmol). After stirring for 16 hours, 1N HCl (50 mL) was added.
The organic layer was collected and washed with water (2x50
mL), dried over anhydrous MgSO₄, filtered, and added to
hexanes to precipitate a tan solid (7.0 g, 96%): mp 70-72 °C.

Step 3: Preparation of 4-[5-(3-fluoro-4-methoxyphenv1)-3-(difluoromethyl)-1H-pyrazol-1-yllbenzenesulfonamide.

35 4,4-Difluoro-1-(3-fluoro-4-methoxypheny1)-butane-1,3-dione from Step 2 (7.0 g, 28.4 mmol) was dissolved in ethanol (150 mL). To the stirred mixture was added 4-sulphonamidopheny1 hydrazine hydrochloride (7.4 g, 33 mmol)

and stirred at reflux overnight (16 hours). The mixture was cooled and water was added until crystals slowly appeared. The product was isolated by filtration and air dried to provide the desired product as a light tan solid (9.8 g, 87%): mp 159-161 °C. Anal. Calc'd. for C17H14N3SO3F3: C, 51.38; H, 3.55; N, 10.57. Found: C, 51.46; H, 3.52; N, 10.63.

Example 3

10

7-[3-[2-(Cyclopropylmethy1)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid is prepared as in U.S. Patent No. 5,310,951, which is incorporated by reference.

Induction and assessment of collagen induced arthritis in mice

20

25

30

15

Arthritis is induced in 8-12 week old male DBA/1 mice by injection of 50 µg of chick type II collagen (CII) (provided by Dr. Marie Griffiths, Univ. of Utah, Salt Lake City, UT) in complete Freunds adjuvant (Sigma) on day 0 at the base of the tail as previously described [J. Stuart, Annual Rev. Immunol., 2, 199 (1984)]. Compounds are prepared as a suspension in 0.5% methylcelluose (Sigma, St. Louis, MO), 0.025% Tween 20 (Sigma). The cyclooxygenase-2 inhibitors (Example 1 and 2) and leukotriene B4 receptor antagonist (Example 3) are administered alone or a cyclooxygenase-2 inhibitor and a leukotriene B4

3.5

receptor antagonist in combination. The compounds are administered in non-arthritic animals by gavage in a volume of 0.1 ml beginning on day 20 post collagen injection and continuing daily until final evaluation 5 on day 55. Animals are boosted on day 21 with 50 μg of collagen (CII) in incomplete Freunds adjuvant. The animals are subsequently evaluated several times each week for incidence and severity of arthritis until day 56. Any animal with paw redness or swelling is counted as arthritic. Scoring of severity is carried out using 10 a score of 0-3 for each paw (maximal score of 12/mouse) as previously described [P. Wooley, et al., Trans. Proc., 15, 180 (1983)]. The animals are measured for incidence of arthritis and severity in the animals where arthritis is observed. The incidence of 15 arthritis is determined at a gross level by observing the swelling or redness in the paw or digits. Severity is measured with the following guidelines. Briefly, animals displaying four normal paws, i.e., no redness or swelling are scored 0. Any redness or swelling of 20 digits or the paw is scored as 1. Gross swelling of the whole paw or deformity is scored as 2. Ankylosis of joints is scored as 3.

25 Histological Examination of Paws

In order to verify the gross determination of a non-arthritic animal, a histological examination is performed. Paws from animals sacrificed at the end of 30 the experiment are removed, fixed and decalcified as previously described [R. Jonsson, J. Immunol. Methods, 88, 109 (1986)]. Samples are paraffin embedded, sectioned, and stained with hematoxylin and eosin by standard methods. Stained sections are examined for cellular infiltrates, synovial hyperplasia, and bone and cartilage erosion.

WO 96/41645 PCT/US96/09905

45

The animals are dosed at one of the following dosing ranges:

```
a - Example 1 @ 3 mpk/day; Example 3 @ 3 mpk/day;
5 b - Example 2 @ 30 mpk/day; Example 3 @ 10 mpk/day;
c - Example 2 @ 10 mpk/day; Example 3 @ 10 mpk/day;
d - Example 1 M,W,F @ 10 mpk/day; Example 3 @ 10 mpk/day.
```

Example 4

10

A formulation is prepared having the following components:

700 mg of a cyclooxygenase-2 inhibitor and 700 mg of a leukotriene B4 receptor antagonist.

15

Example 5

A formulation is prepared having the following components:

350 mg of 4-[5-(3-fluoro-4-methoxypheny1)-3-(difluoromethy1)-1H-pyrazo1-1-y1) benzenesulfonamide and 350 mg of 7-[3-[2-(cyclopropylmethy1)-3-methoxy-4-[(methylamino)carbony1]phenoxy]propoxy]-3,4-dihydro-8-propy1-2H-1-benzopyran-2-propanoic acid.

25

20

Also embraced within this invention is a class of pharmaceutical compositions comprising the active compounds of this combination therapy in association with one or more non-toxic, pharmaceutically-30 acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the 35 form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and composition may, for example, be administered orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically. 40

20

30

35

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.

The amount of therapeutically active compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of 15 factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain active ingredients in the range of about 0.1 to 2000 mg, preferably in the range of about 0.5 to 500 mg and most preferably between about 1 and 100 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.5 and about 20 mg/kg body 25 weight and most preferably between about 0.1 to 10 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day.

In the case of psoriasis and other skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.

For inflammations of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w. preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active

ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of 10 the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be 15 administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the 20 reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of 25 microcapsules, the encapsulating agent may also function as the membrane.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and

30

fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearvl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic 10 properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other 15 containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a 20 blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The antiinflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w.

For therapeutic purposes, the active compounds 35 of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose,

sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a 10 dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various 20 buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. Although this invention has been described with


Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

What is claimed is :

30

35

- A combination comprising a therapeuticallyeffective amount of a cyclooxygenase-2 inhibitor and a
 leukotriene B₄ receptor antagonist.
 - A combination comprising a therapeuticallyeffective amount of a leukotriene B₄ receptor antagonist
 and a cyclooxygenase-2 inhibitor selected from Taisho
 NS-398, meloxicam, floculide, Merck MK-966, Merck L752,860 and compounds of Formula I



wherein A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings:

wherein R¹ is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, 20 wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and 25 alkylthio;

wherein R² is methyl or amino; and wherein R³ is a radical selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylchioalkyl, aryloxyalkyl, aralkylthioalkyl, arylchioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl,

aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonyl, alkylamino, N-arylamino, N-aralkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, alkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, aryloxy, aralkoxy, aryltnio, aralkyltnio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl;

or a pharmaceutically-acceptable salt thereof.

- The combination of Claim 2 wherein the 15 leukotriene B4 receptor antagonist is selected from Baver Bav-x-1005, Ciba-Geigy CGS-25019C, ebselen, Leo Denmark ETH-615, Lilly LY-293111, Ono ONO-4057, Terumo TMK-688, Boehringer Ingleheim BI-RM-270, Lilly LY 213024, Lilly LY 264086, Lilly LY 292728, Ono ONO LB457, Pfizer 105696, Perdue Frederick PF 10042, Rhone-20 Poulenc Rorer RP 66153, SmithKline Beecham SB-201146, SmithKline Beecham SB-201993, Searle SC-53228, Sumitamo SM 15178, American Home Products WAY 121006, Bayer Bayo-8276, calcitriol, Warner-Lambert CI-987, Merck and 25 Co. L-651392, Lilly LY 210073, Lilly LY 223982, Lilly LY 233569, Lilly LY-255283, Merck and Co. MK-591, Merck and CO. MK-886, Ono ONO-LB-448, Purdue Frederick PF-5901, Rhone-Poulenc Rorer RG 14893, Rhone-Poulenc Rorer RP 66364, Rhone-Poulenc Rorer RP 69698, Searle SC-30 41930, Searle SC-50505, Searle SC-51146, SmithKline Beecham SK&F-104493, and Teijin TEI-1338.
 - 4. The combination of Claim 3 wherein the leukotriene B₄ receptor antagonist is selected from Bayer Bay-x-1005, Ciba-Geigy CGS-25019C, ebselen, Leo Denmark ETH-615, Lilly LY-293111, Ono ONO-4057, Terumo TMK-688, Boehringer Ingleheim BI-RM-270, Lilly LY

213024, Lilly LY 264086, Lilly LY 292728, Ono ONO LB457, Pfizer 105696, Perdue Prederick PF 10042, Rhone-Poulenc Rorer RP 66153, SmithKline Beecham SB-201146, SmithKline Beecham SB-201993, Searle SC-53228, Sumitamo SM 15178, and American Home Products WAY 121006.

- 5. The combination of Claim 4 wherein the leukotriene B4 receptor antagonist is selected from Bayer Bay-x-1005, Ciba-Geigy CGS-25019C, ebselen, Leo Denmark ETH-615, Lilly LY-293111, Ono ONO-4057, and Terumo TMK-688.
- 6. The combination of Claim 2 wherein A is selected from 5- or 6-member partially unsaturated heterocyclyl, 15 5- or 6-member unsaturated heterocyclyl, 9- or 10-member unsaturated condensed heterocyclyl, lower cycloalkenyl and phenyl; wherein R1 is selected from 5- and 6membered heterocyclyl, lower cycloalkyl, lower cycloalkenvl and aryl selected from phenyl, biphenyl and 20 naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxvl, lower alkoxvcarbonvl, hvdroxvl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, 25 phenylamino, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio; wherein R2 is methyl or amino; and wherein R3 is a radical selected from hydrido, oxo, cyano, carboxyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, 30 halo, lower alkyl, lower alkyloxy, lower cycloalkyl, phenyl, lower haloalkyl, 5- or 6-membered heterocyclyl, lower hydroxylalkyl, lower aralkyl, acyl, phenylcarbonyl, lower alkoxyalkyl, 5- or 6-membered heteroaryloxy, aminocarbonyl, lower alkylaminocarbonyl, lower alkylamino, lower aminoalkyl, lower 35 alkylaminoalkyl, phenyloxy, and lower aralkoxy; or a pharmaceutically-acceptable salt thereof.

7. The combination of Claim 6 wherein A is selected from oxazolyl, isoxazolyl, thienyl, dihydrofuryl, furyl, pyrrolyl, pyrazolyl, thiazolyl, imidazolyl, isothiazolyl, benzofuryl, cyclopentenyl, cyclopentadienyl, phenyl, and pyridyl; wherein R1 is selected from pyridyl optionally substituted at a substitutable position with one or more methyl radicals, and phenyl optionally substituted at a 10 substitutable position with one or more radicals selected from methyl, ethyl, isopropyl, butyl, tertbutyl, isobutyl, pentyl, hexyl, cyano, fluoromethyl, difluoromethyl, trifluoromethyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, hydroxymethyl, trifluoromethoxy, hydroxyl, amino, N-methylamino, N.N-15 dimethylamino, N-ethylamino, N,N-dipropylamino, Nbutylamino, N-methyl-N-ethylamino, phenylamino, methoxymethyl, methylsulfinyl, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, and methylthio; wherein R2 is methyl or amino; and wherein 20 R3 is a radical selected from hydrido, oxo, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, carboxypropyl, carboxymethyl, carboxyethyl, cyanomethyl, fluoro, chloro, bromo, methyl, ethyl, 25 isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, difluoroethyl, difluoropropyl, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, cyclohexyl, phenyl, pyridyl, thienyl, thiazolyl, 30 oxazolyl, furyl, pyrazinyl, hydroxylmethyl, hydroxylpropyl, benzyl, formyl, phenylcarbonyl, methoxymethyl, furylmethyloxy, aminocarbonyl, Nmethylaminocarbonyl, N,N-dimethylaminocarbonyl, N,Ndimethylamino, N-ethylamino, N,N-dipropylamino, N-35 butylamino, N-methyl-N-ethylamino, aminomethyl, N,N-

dimethylaminomethyl, N-methyl-N-ethylaminomethyl,

benzyloxy, and phenyloxy; or a pharmaceuticallyacceptable salt thereof.

- 8. The combination of Claim 7 selected from compounds, their prodrugs and their pharmaceuticallyacceptable salts, of the group consisting of
 - 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole;
- 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-10 3-(trifluoromethyl)pyrazole;
 - 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1yl)benzenesulfonamide
 - 4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-
- 15 v1) benzenesulfonamide:
 - 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1yl)benzenesulfonamide;
 - 4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1v1)benzenesulfonamide;
- 20 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1vl)benzenesulfonamide;
 - 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1v1)benzenesulfonamide:
- 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-25 v1)benzenesulfonamide:
 - 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1
 - yl)benzenesulfonamide
 - 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1vllbenzenesulfonamide;
- 30 4-[5-phenvl-3-(trifluoromethvl)-1H-pvrazol-1vllbenzenesulfonamide;
 - 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1vl]benzenesulfonamide:
- 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1vl]benzenesulfonamide; 35
 - 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1vl]benzenesulfonamide;

- 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1vl]benzenesulfonamide;
- 4-[4-chloro-5-(4-chloropheny1)-3-(trifluoromethy1)-1Hpyrazol-1-y1]benzenesulfonamide;
- 5 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1vl]benzenesulfonamide;
 - 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1v1)benzenesulfonamide;
 - 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-
- 10 yl]benzenesulfonamide;
 - 4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1yl]benzenesulfonamide;
 - 4-[3-(difluoromethy1)-5-(3-fluoro-4-methoxypheny1)-1Hpyrazo1-1-y1]benzenesulfonamide;
- 15 4-[5-(3-fluoro-4-methoxypheny1)-3-(trifluoromethy1)-1Hpyrazol-1-y1]benzenesulfonamide;
 - 4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
 - 4-[5-(4-chloropheny1)-3-(hydroxymethy1)-1H-pyrazo1-1y1]benzenesulfonamide;
- 20 4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl]benzenesulfonamide;
 - 5-(4-fluorophenyl)-6-[4 (methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
 - 4-[6-(4-fluorophenyl)spiro[2.4]hept-5-en-5-
- 25 yl]benzenesulfonamide;
 - 6-(4-fluorophenyl)-7-[4-
 - (methylsulfonyl)phenyl]spiro[3.4]oct-6-ene;
 - 5-(3-chloro-4-methoxyphenyl)-6-[4(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
- 30 4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5yl]benzenesulfonamide;
 - 5-(3,5-dichloro-4-methoxyphenyl)-6-[4-
 - (methy1sulfony1)pheny1]spiro[2.4]hept-5-ene;
 5-(3-chloro-4-fluoropheny1)-6-[4-
- 35 (methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
 - 4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5yl]benzenesulfonamide;

WO 96/41645 PCT/US96/09905

2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4methylsulfonylphenyl)thiazole;

56

- 2-(2-chloropheny1)-4-(4-fluoropheny1)-5-(4methylsulfonylphenyl)thiazole;
- 5 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2methylthiazole:
 - 4-(4-fluoropheny1)-5-(4-methylsulfonylpheny1)-2trifluoromethylthiazole:
 - 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2thienvl)thiazole;
- 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2benzvlaminothiazole;
 - 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1propylamino)thiazole;
- - 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2trifluoromethylthiazole;
 - 1-methylsulfonyl-4-[1,1-dimethyl-4-(4-
 - fluorophenyl)cyclopenta-2,4-dien-3-yl]benzene;
 - 4-[4-(4-fluoropheny1)-1,1-dimethylcyclopenta-2,4-dien-3y1]benzenesulfonamide;
 - 5-(4-fluorophenyl)-6-[4-

10

20

- (methylsulfonyl)phenyl]spiro[2.4]hepta-4,6-diene;
- 25 4-[6-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-5yl]benzenesulfonamide;
 - 6-(4-fluoropheny1)-2-methoxy-5-[4-(methylsulfony1)pheny1]pyridine-3-carbonitrile;
 - 2-bromo-6-(4-fluoropheny1)-5-[4-(methylsulfony1)pheny1]pyridine-3-carbonitrile;
 - 6-(4-fluoropheny1)-5-[4-(methylsulfony1)pheny1]-2-phenylpyridine-3-carbonitrile;
 - 4-[2-(4-methylpyridin-2-y1)-4-(trifluoromethyl)-lHimidazol-1-yl]benzenesulfonamide;
- 35 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1Himidazol-1-vllbenzenesulfonamide:

- 4-[2-(2-methylpyridin-3-y1)-4-(trifluoromethyl)-1Himidazol-1-yl]benzenesulfonamide;
- 3-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1Himidazol-2-vllpvridine;
- 5 2-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1Himidazol-2-yl]pyridine;
 - 2-methyl-4-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- 2-methyl-6-[1-[4-(methylsulfonyl)phenyl-4-
- 10 (trifluoromethyl)-1H-imidazol-2-yl)pyridine;
 - 4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1Himidazol-1-yl]benzenesulfonamide;
 - 2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;
- - 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-methyl1H-imidazole;
- 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-phenyl-20 1H-imidazole;
 - 2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-1H-imidazole;
 - 2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazole;
- 25 1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole;
 - 2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4trifluoromethyl-1H-imidazole;
- 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H30 imidazol-1-yl]benzenesulfonamide;
 - 2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]4-(trifluoromethyl)-1H-imidazole;
 - 4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1Himidazol-1-yl]benzenesulfonamide;
- 35 2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4trifluoromethyl-1H-imidazole;

PCT/US96/09905 WO 96/41645

4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1yl]benzenesulfonamide;

1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4trifluoromethyl-1H-imidazole;

58

- 4-[2-(3-chlorophenvl)-4-trifluoromethvl-1H-imidazol-1vllbenzenesulfonamide:
 - 4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1vllbenzenesulfonamide:
- 4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-
- 10 imidazol-1-yl]benzenesulfonamide;

- 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1Hpyrazol-3-yl!benzenesulfonamide:
- N-phenyl-[4-(4-luorophenyl)-3-[4-(methylsulfonyl)phenyl]-15 5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
 - ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
 - 4-(4-fluorophenvl)-3-[4-(methylsulfonvl)phenvl]-1-(2phenylethyl)-1H-pyrazole;
 - 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2phenylethyl)-5-(trifluoromethyl)pyrazole;
 - 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-25 trifluoromethyl-1H-imidazole;
 - 4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-
 - (trifluoromethyl)-1H-imidazole;
- 5-(4-fluorophenyl)-2-methoxy-4-[4-(methylsulfonyl)phenyl]-30 6-(trifluoromethyl)pyridine;
 - 2-ethoxy-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine:
 - 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-(2propynyloxy)-6-(trifluoromethyl)pyridine;
- 2-bromo-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-35 (trifluoromethyl)pyridine:

PCT/US96/09905 WO 96/41645

59

```
4-[2-(3-chloro-4-methoxyphenyl)-4,5-
  difluorophenyllbenzenesulfonamide;
```

- 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]benzene;
- 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-
- - 4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
 - 4-[5-difluoromethyl-3-phenylisoxazol-4
 - yl]benzenesulfonamide;
 - 4-[5-hvdroxvmethvl-3-phenvlisoxazol-4-
- yl]benzenesulfonamide; 10

phenylisoxazole:

5

25

- 4-[5-methyl-3-phenyl-isoxazol-4-vl]benzenesulfonamide;
- 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-
- 15 (methylsulfonvl)benzene;
 - 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - 1-[2-(2,4-dichlorophenyl)cvclopenten-1-vl]-4-(methylsulfonyl)benzene;
- 20 1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - 1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonvl)benzene;
 - 1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-
- (methylsulfonyl)benzene; 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-
 - 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 30 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1vllbenzenesulfonamide:
 - 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
 - 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide;
 - 1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-
- 35 (methylsulfonyl)benzene;

yl]benzenesulfonamide;

1-[2-(2,3-difluorophenyl)cyclopenten-1-v1]-4-(methylsulfonyl)benzene;

4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1y1]benzenesulfonamide;

- 1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-4(methylsulfonyl)benzene;
- 5 4-[2-(3-chloro-4-fluoropheny1)cyclopenten-1-yl]benzenesulfonamide;
 - 4-[2-(2-methylpyridin-5-yl)cyclopenten-1yl]benzenesulfonamide;


ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)

10 phenyl]oxazol-2-yl]-2-benzyl-acetate;

2-[4-(4-fluorophenyl)-5-[4-

(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid;

- 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4(methylsulfonyl)phenyl]oxazole;
- 15 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2phenyloxazole;
 - 4-(4-fluorophenyl)-2-methyl-5-[4 (methylsulfonyl)phenyl]oxazole; and
 - 4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-
- 20 oxazolyl]benzenesulfonamide.
- 9. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a leukotriene B₄
 25 receptor antagonist and a cyclooxygenase-2 inhibitor selected from Taisho NS-398, meloxicam, floculide, Merck MK-966, Merck L-752.860 and compounds of Formula I



30

wherein A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

30 "

wherein R^1 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R^1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R2 is methyl or amino; and wherein R3 is a radical selected from hydrido, 10 halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, 15 acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arvlcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, 20 N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, Narylamino, N-aralkylamino, N-alkyl-N-aralkylamino, Nalkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, Narvlaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-25 aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, Narylaminosulfonyl, arylsulfonyl, N-alkyl-Narvlaminosulfonyl;

or a pharmaceutically-acceptable salt thereof.

10. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising co-administering to the subject having or susceptible to such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a leukotriene B4 receptor antagonist and a

10

cyclooxygenase-2 inhibitor selected from Taisho NS-398, meloxicam, floculide, Merck MK-966, Merck L-752,860 and compounds of Formula I

wherein A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

wherein \mathbb{R}^1 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein \mathbb{R}^1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R2 is methyl or amino; and wherein R3 is a radical selected from hydrido. 20 halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, 25 arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxvalkyl, alkoxvaralkoxvalkyl, alkoxvcarbonvlalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-30 arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, Nalkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, Narylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-Naralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy,

PCT/US96/09905

10

30

aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl;

or a pharmaceutically-acceptable salt thereof.

- 11. The method of Claim 10 wherein said leukotriene B_4 receptor antagonist and said cycloxygenase-2 inhibitor are administered in a sequential manner.
- 12. The method of Claim 10 wherein said leukotriene B_4 receptor antagonist and said cycloxygenase-2 inhibitor are administered in a substantially simultaneous manner.
- 15 13. The method of Claim 10 wherein the leukotriene B_4 receptor antagonist is selected from compounds of Claim 4.
- 14. The method of Claim 13 wherein the leukotriene 20 B₄ receptor antagonist is selected from compounds of Claim 5.
- 15. The method of Claim 10 wherein the cyclooxygenase-2 inhibitor is selected compounds of Claim 6, or a pharmaceutically-acceptable salt thereof.
 - 16. The method of Claim 15 wherein the cyclooxygenase-2 inhibitor is selected compounds of Claim 7, or a pharmaceutically-acceptable salt thereof.
 - 17. The method of Claim 16 wherein the cyclooxygenase-2 inhibitor is selected compounds of Claim 8, or a pharmaceutically-acceptable salt thereof.
- 35 18. The method of Claim 10 wherein the condition is inflammation.

WO 96/41645 PCT/US96/09905

64

- 19. The method of Claim 10 wherein the condition is an inflammation-associated disorder.
- 20. The method of Claim 19 wherein the inflammation-associated disorder is arthritis.
 - 21. The method of Claim 10 wherein the subject is susceptible to inflammation.
- 10 22. The method of Claim 10 wherein the subject is susceptible to an inflammation-associated disorder.
 - $23\,.\,$ The method of Claim 22 wherein the subject is susceptible to arthritis.

International Application No PCT/US 96/09905

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUM	IENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	DE,A,42 28 201 (SCHERING AG) 3 March 1994 see page 6, line 55 - line 59	1
X,P	WO,A,96 03385 (SEARLE & CO ;LEE LEN F (US); PENNING THOMAS D (US); KRAMER STEVEN) 8 February 1996 see page 5, paragraph 3-4	1-23
X,P	WO,A,96 03388 (SEARLE & CO; KHANNA ISH K (US); WEIER RICHARD M (US); COLLINS PAUL) 8 February 1996 cited in the application see page 6, line 1 - line 19 see abstract	1-23

*Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date "L" document which may throw doubte on priority claim(q) or which is cited to establish the publication date of another which is cited to establish the publication date of another "O" document veferring to an oral disclosure, use, exhibition or other means." P" document published prior to the international filing date but laier than the priority date claim.	X' document of particular relevance; the claimed invention cannot be considered now of cannot be considered now of annot be considered and to involve an inventive step when the document is taken alone. Y document of particular relevance; the claimest invention of the consideration of the considerati
Date of the actual completion of the international search	Date of mailing of the international search report
27 November 1996	0 5. 12. 96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax (+31-70) 340-3016	Authorized officer Leherte, C

Form PCT/ISA/210 (second sheet) (July 1992)

Further documents are listed in the continuation of box C.

X Patent family members are listed in annex.

International Application No PCT/US 96/09905

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages 1-23 WO.A.96 03387 (SEARLE & CO ; WEIER RICHARD X.P M (US); COLLINS PAUL W (US); STEALEY MI) 8 February 1996 cited in the application see page 8, line 2-21 see abstract 1-23 US.A.5 510 368 (LAU CHEUK K ET AL) 23 P.Y April 1996 cited in the application see abstract 1-23 WO.A.95 15316 (SEARLE & CO ; TALLEY JOHN J Υ (US); PENNING THOMAS D (US); COLLINS PA) 8 June 1995 cited in the application see abstract 1-23 WO.A.94 26731 (MERCK FROSST CANADA INC :GAUTHIER JACQUES YVES (CA); LEBLANC YVES) 24 November 1994 cited in the application see abstract 1-23 WO.A.95 00501 (MERCK FROSST CANADA INC ;DUCHARME YVES (CA); GAUTHIER JACQUES YVES) 5 January 1995 cited in the application see abstract see page 26, line 1-21 WO.A.94 20480 (MERCK FROSST CANADA INC 1-23 ٧ BLACK CAMERON W (CA); GUAY DANIEL (CA); L) 15 September 1994 cited in the application see abstract WO.A.94 13635 (MERCK FROSST CANADA INC 1-23 Υ : FORD HUTCHINSON ANTHONY W (CA): KENNEDY B) 23 June 1994 cited in the application see abstract WO.A.94 15932 (SEARLE & CO ; MONSANTO CO 1-23 γ (US); BERTENSHAW STEPHEN R (US); COLLINS) 21 July 1994 cited in the application see abstract US.A.5 246 965 (MAIN ALAN J) 21 September 1-23 γ 1993 cited in the application see abstract -/--

International Application No PCT/US 96/09905

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Category * | Citation of document, with indication, where appropriate, of the relevant passages 1-23 US.A,5 384 318 (EGGLER JAMES F ET AL) 24 Υ January 1995 cited in the application see abstract 1-23 WO.A.94 27980 (SEARLE & CO ; NORMAN BRYAN H Υ (US); LEE LEN F (US); MASFERRER JAIME) 8 December 1994 cited in the application see abstract 1-23 US,A,5 344 991 (REITZ DAVID B ET AL) 6 γ September 1994 cited in the application see abstract 1-23 US,A,5 393 790 (REITZ DAVID B ET AL) 28 Υ February 1995 cited in the application see abstract

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

PCT/US 96/09905

BOX 1 Observations where certain claims were found unsearchable (Continuation of Rem 1 of 1854 Sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
Claims Nor.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim(s) 10-23	
is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.	
Claims Noz.: 1-23 Claims Noz.: 1-23 Claims Noz.: 1-23 Claims Noz.: 1-24 Claims Noz.: 1-25 Claims Noz.: 1-25	
In view of the large number of compounds which are defined by the wording of the claims, the search has been performed on the general idea and compounds mentioned in the examples of the description.	
 Claims Not.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). 	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
2. As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Noc.:	
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nor.:	
Remark on Protest The additional search fees were accompanied by the applicant's protest.	
No protest accompanied the payment of additional search fees.	

INTERNATIONAL SEARCH REPORT International Application No

Information on patent family members

PCT/US 96/09905

Information on patent family members			PCT/US 96/09905	
Patent document Publication Patent far ited in search report date member(ily s)	Publication date	
DE-A-4228201	03-03-94	CA-A- WO-A- EP-A- HU-A-	4950593 2142821 9404522 0656896 70511 8500585 950708 5559134	15-03-94 03-03-94 03-03-94 14-06-95 30-10-95 23-01-96 24-02-95 24-09-96
WO-A-9603385	08-02-96	US-A- AU-A-	5486534 3126795	23-01-96 22-02-96
WO-A-9603388	08-02-96	AU-A-	3202595	22-02-96
WO-A-9603387	08-02-96	AU-A-	3271695	22-02-96
US-A-5510368	23-04-96	NONE		
WO-A-9515316	08-06-95	US-A- US-A- AU-A- CA-A- EP-A- F1-A- NO-A- US-A- US-A- US-A- US-A- US-A-	5466823 5521207 1171495 2177576 0731795 962249 962184 314695 5510496 5510496 55108426 5516907 5504215 9409418	14-11-95 28-95-96 19-96-95 08-96-95 18-09-96 29-95-96 16-09-96 08-10-96 08-10-96 14-05-96 02-04-96 02-04-96
WO-A-9426731 WO-A-9500501	24-11-94 05-01-95	AU-A- US-A- AU-A- AU-A- BG-A- BR-A-	6718494 5474995 6197096 6967494 100247 9406979	12-12-94 12-12-95 31-10-96 17-01-95 28-06-96 05-03-96

Information on patent family members

International Application No PCT/US 96/09905

Patent document cited in search report	Publication date	Patent fami member(s	ly	Publication date
WO-A-9500501		CA-A- 2	163888 176973	05-01-95 25-12-94 25-12-94
			176974 125944	03-07-96
ļ.			503146	15-05-96
			705254	10-04-96
			956119	19-12-95
			955256	23-02-96
			312196	01-04-96
			536752	16-07-96
			550142	27-08-96
		ZA-A- 9	404501	13-03-95
		AU-A- 1	269495	01-08-95
		CA-A- 2	180651	13-07-95
		WO-A- 9	518799	13-07-95
			739340	30-10-96
			962800	06-09-96
		NO-A-	960393	09-07-96
WO-A-9420480	15-09-94	AU-A- 6	409944 178894	25-04-95 26-09-94
		CA-A- 2	157107	14-09-94
WO-A-9413635	23-06-94		621594 151235	04-07-94 23-06-94
			673366	27-09-95
			504408	14-05-96
WO-A-9415932	21-07-94		027694 152792	15-08-94 21-07-94
			679157	02-11-95
US-A-5246965	21-09-93		807292	17-12-92
			070796	12-12-92
		EP-A- 0: HU-A-	518818 61977	16-12-92 29-03-93
			239008	17-09-93
US-A-5384318	24-01-95	WO-A- 9	015801	27-12-90
	2. 01-33		19349	22-12-90

Information on patent family members

International Application No PCT/US 96/09905

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5384318		EP-A- 0404440 FI-B- 96951 JP-A- 3038569 JP-B- 7053722	27-12-90 14-06-96 19-02-91 07-06-95
WO-A-9427980	08-12-94	US-A- 5380738 AU-A- 6949594 EP-A- 0699192	10-01-95 20-12-94 06-03-96
US-A-5344991	06-09-94	AU-A- 7365094 CA-A- 2170736 EP-A- 0724566 WO-A- 9511883 US-A- 5420287	22-05-95 04-05-95 07-08-96 04-05-95 30-05-95
US-A-5393790	28-02-95	AU-A- 1740895 CA-A- 2182950 EP-A- 0743938 W0-A- 9521817 ZA-A- 9501107	29-08-95 17-08-95 27-11-96 17-08-95 12-02-96